Abstract:Urogenital schistosomiasis caused by Schistosoma haematobium affects approximately 110 million people globally, with the majority of cases in low- and middle-income countries. Schistosome infections have been shown to impact the host immune system, gene expression, and microbiome composition. Studies have demonstrated variations in pathology between schistosome subspecies. In the case of S . haematobium , infection has been associated with HIV acquisition and bladder cancer. However, the underlying pathophysiology has been understudied compared to other schistosome species. This systematic review comprehensively investigates and assimilates the effects of S . haematobium infection on systemic and local host mucosal immunity, cellular gene expression and microbiome. We conducted a systematic review assessing the reported effects of S . haematobium infections and anthelmintic treatment on the immune system, gene expression and microbiome in humans and animal models. This review followed PRISMA guidelines and was registered prospectively in PROSPERO (CRD42022372607). Randomized clinical trials, cohort, cross-sectional, case-control, experimental ex vivo , and animal studies were included. Two reviewers performed screening independently. We screened 3,177 studies and included 94. S . haematobium was reported to lead to: (i) a mixed immune response with a predominant type 2 immune phenotype, increased T and B regulatory cells, and select pro-inflammatory cytokines; (ii) distinct molecular alterations that would compromise epithelial integrity, such as increased metalloproteinase expression, and promote immunological changes and cellular transformation, specifically upregulation of genes p53 and Bcl-2 ; and (iii) microbiome dysbiosis in the urinary, intestinal, and genital tracts. S . haematobium induces distinct alterations in the host's immune system, molecular profile, and microbiome. This leads to a diverse range of inflammatory and anti-inflammatory responses and impaired integrity of the local mucosal epithelial barrier, elevating the risks of secondary infections. Further, S . haematobium promotes cellular transformation with oncogenic potential and disrupts the microbiome, further influencing the immune system and genetic makeup. Understanding the pathophysiology of these interactions can improve outcomes for the sequelae of this devastating parasitic infection. The parasitic trematode S . haematobium affects 110 million people worldwide. Many studies have described the effects of schistosome infections on humans and animals, but data focusing solely on S . haematobium infections, which cause urogenital schistosomiasis are scarce. Our goal was to evaluate, in a systematic manner, how S . haematobium infection affects the immune system, gene expression and microbiome of the host. These effects are important because they could lead to increased risk of infections, such as HIV, and bladder cancer. We screened 3,179 studies for potential relevance and included 94 of them in this review. Our analysis showed that S . haematobium infection profoundly alters the immune system with a mixed pro-inflammatory and anti-inflammatory response, though with a predominant type 2 immune phenotype and increased regulatory cells. We further found consistent evidence that it impairs local mucosal epithelial barrier integrity, promotes cellular transformation with pro-oncogenic changes in the host, and is associated with microbial alterations in urine, stool, and genital tracts. We discuss how these findings might be interpreted, and the additional research needed, to improve our understanding of S . haematobium pathophysiology and ameliorate the potential sequelae of S . haematobium infection, such as increased viral infections and cancer.

Experimental Schistosoma haematobium pulmonary hypertension

Bmpr-Ii Deficiency Leads to an Increase in Egg Deposition and Cytokine Release in the Lungs of Mice Chronically Infected with Schistosomiasis

S34 Bmpr-ii Deficiency Leads to an Increase in Lung Egg Deposition, Pulmonary Vascular Remodelling and an Abnormal Liver Vasculature in Mice Chronically Infected with S. Mansoni

Schistosomiasis-associated pulmonary hypertension unveils disrupted murine gut-lung microbiome and reduced endoprotective Caveolin-1/BMPR2 expression

Interstitial macrophage phenotypes in Schistosoma-induced pulmonary hypertension

Intrapulmonary T Cells Are Sufficient for Schistosoma-Induced Pulmonary Hypertension

Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review

Pulmonary Hypertension as a Primary Presentation for Schistosomiasis, a Case Report of Unusual Presentation

Schistosoma haematobium total antigen induces increased proliferation, migration and invasion, and decreases apoptosis of normal epithelial cells

Schistosome Infection Impacts Hematopoiesis

Whole-genome Sequence of Schistosoma Haematobium.

Isolation of Schistosoma haematobium in Bronchoalveolar Lav-age in an Immunocompromised Individual: A Case Report

Schistosoma mansoni: influence of infection on mouse behavior

The pathobiology of Schistosoma haematobium infection in humans

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection

Dietary glycemic and energy load differentially modulates Schistosoma mansoni-induced granulomatous inflammation and response to antiparasitic chemotherapy

Re-assessing thermal response of schistosomiasis transmission risk: evidence for a higher thermal optimum than previously predicted

Schistosoma mansoni enhances host susceptibility to mucosal but not intravenous challenge by R5 Clade C SHIV

Schistosoma Japonicum: Modern Tools for an Ancient Disease

Helminth Infection Impacts Hematopoiesis

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni